此透射电子显微镜图像显示出T细胞的横截面，图中的“泡泡”是成长中的爱滋病病毒
【搜狐科学消息】 据英国《新科学家》杂志报道，美国研究人员利用基因转移技术开发出一种新型艾滋病疫苗，该方法完全绕过了激活人体天然免疫系统反应这一常规途径，通过将携带类抗体蛋白的腺群病毒注射入猕猴肌肉中，就能制造出附着性免疫蛋白，从而成功使猕猴对一种与艾滋病病毒极为相似的猿猴免疫缺陷病毒（SIV）产生了免疫功能。该成果为人类艾滋病疫苗的研究带来了新希望。
相关研究当日发表在最新出版的《自然-医学》杂志网络版上。
研究表明，9只注射这种新型疫苗的猕猴成功抵抗了SIV病毒的侵袭。这种新型疫苗绕过了猕猴的免疫系统，而是将猕猴的肌肉变成了抗体工厂，有效杀死了SIV病毒。
新型疫苗违背了常规方法。众所周知，常规办法常常使用一种物质激活人体免疫系统，使其产生抗体，以期消灭病毒。然而临床试验的结果并不乐观，正如人体自身不能产生有效反应来防止艾滋病感染一样，艾滋病疫苗也无法引起保护性免疫反应。相反，负责该研究的美国费城儿童医院首席科学家菲利普·约翰逊博士和他的同事则采取了跨越式技术，绕过了先前研究所关注的天然免疫系统反应，另辟蹊径，通过无害病毒携带能生产附着性免疫蛋白(immunoadhesins) 的类抗体蛋白的基因，采用基因转移技术，达到了防止感染艾滋病的目的。
具体办法是：研究人员首先创建一种被称之为附着性免疫蛋白(immunoadhesins)的类抗体蛋白，这种蛋白具有抗SIV病毒的作用。在证实其能够有效防止SIV感染后，研究人员通过基因转移技术，将此蛋白置入腺群病毒(AAV)。之后，研究人员将携带这种类抗体蛋白的腺群病毒注射到9只猕猴的肌肉细胞核中，让肌肉生产出附着性免疫蛋白。1个月后，再对这些猕猴注入SIV病毒。结果表明，所有接受过疫苗注射的猕猴均未出现艾滋病症状。而且85周之后，这些猕猴血液中还存有较高浓度的类SIV抗体。而未进行免疫注射的6只猕猴则均被SIV感染，且4只死于艾滋病并发症。（元元）
New HIV vaccine can become antibody factories muscle (Figure)
At 9:02 on May 26, 2009 Source: Sohu Science
This transmission electron microscope images show that T cell cross-section, map the "bubble" is the growing HIV
Science news】 【Sohu, according to the United Kingdom, "New Scientist" magazine reported that U.S. researchers have used gene transfer technology to develop a new type of AIDS vaccine, the method completely bypass the activation of the human innate immune system response of the conventional way, by carrying type gland protein antibody group virus was injected into the muscles in monkeys can produce immune adhesion protein, thus the success of a monkey with AIDS virus is very similar to the simian immunodeficiency virus (SIV) resulted in immune function. The results for human AIDS vaccine research has brought new hope.
The date of the relevant research published in the latest issue of "Nature - Medicine" magazine online.
Studies have shown that injection of nine monkeys in this new vaccine has been successful resistance to SIV viruses. The new vaccine to bypass the monkey's immune system, but will be turned into a monkey muscle antibody factories, effectively killing the SIV virus.
Contrary to the conventional novel vaccine approach. As we all know, the conventional approach to a substance often used to activate the body's immune system to produce antibodies, with a view to eliminate the virus. However, the results of clinical trials are not optimistic, as the body's own can not produce an effective response to prevent HIV infection, the AIDS vaccine can not cause a protective immune response. In contrast, the United States is responsible for the study of Philadelphia Children's Hospital chief scientist, Dr. Philip Johnson and his colleagues were taken by leaps and bounds in technology, bypassing the previous Institute of concern to the natural immune system response, open a new path, through the sound can be produced to carry the virus attachment immune protein (immunoadhesins) the type of antibody protein gene, using gene transfer technology, to achieve the purpose of preventing HIV infection.
The specific method is: First of all, the researchers referred to as the creation of an immune protein attachment (immunoadhesins) the type of antibody protein, this protein has a role in anti-SIV virus. Confirmed its ability to effectively prevent SIV infection, the researchers through gene transfer technology, this group of proteins into the adeno-virus (AAV). After, the researchers will carry this type of antibody protein in adeno-group virus injected into the muscle of nine monkeys in the nucleus, so that the muscles attached to produce immune proteins. 1 month after injection of these monkeys SIV virus. The results showed that all vaccinated monkeys had had no symptoms of AIDS. And after 85 weeks, these monkeys also have higher blood concentrations of type SIV antibodies. Not to carry out immunization were six monkeys were infected with SIV, and four died of AIDS complications. (Yuan million)
